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Receptors for the Fc domain of IgG (FcR)' are present on the membranes of
cells of the myeloid and monocytic lineages (1) as well as on other unrelated cell
types (2-4) . Myelomonocytic cells interact with IgG antibody-sensitized cells or
pathogenic organisms through their FcR : this interaction results in the activation
of cellular defense mechanisms, such as antibody-dependent cell-mediated cyto-
toxicity (Ab-CMC), phagocytosis, and the extracellular release of lysosomal
enzymes (5, 6) . FcR are first detected at the promyelocyte stage of myeloid
differentiation, and their expression increases at later stages of maturation (3,
7) .
An FcR that binds human monomeric immunoglobulins of the IgGI class (8-
12) has been purified by immunoabsorption to human IgGI from both freshly
isolated human monocytesand the macrophage cell line U937 (12) . This 73,000-
dalton molecule is not detectable on normal peripheral blood polymorphonuclear
cells (PMN) using the same technique . Two antibodies, 3G8 (13) and B73.1 (14,
15), precipitate a molecule of 50,000-70,000 daltons from PMN and from
natural killer/killer cells respectively : both antibodies inhibit binding ofimmune
complexes to PMN (13-15). Antibody B73.1 also induces modulation of FcR on
natural killer cells and inhibits antibody-dependent cytotoxicity (Ab-CMC) me-
diated by killer cells and PMN probably by reaction with the FcR itself or a
closely related structure (14) . Binding of immune complexes to FcR of both
monocytes and PMN is preferentially inhibited by human IgGI and IgG3 (11,
16) . The available data suggest that, as in the mouse, there are at least two
human FcR for IgG ; the human monocyte FcR is analogous to the mouse
macrophage FcRl (trypsin-sensitive, specifically binding to monomeric mouse
IgG2a) (17, 18), whereas the PMN and natural killer cell FcR correspond
structurally and in binding properties to the mouse macrophage FcR2 (trypsin-
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resistant, preferentially binding complexed mouse IgGI and IgG2b) (17, 18).
Human monocytes cultured in vitro might bear both types of receptors, based
on the reactivity ofantibody 3G8 with -20% of cultured human monocytesand
its ability to inhibit phagocytosis of E-IgGI complexes (13) by these cells. A
trypsin-sensitive receptor, specific for aggregated mouse IgG3, has been de-
scribed on mouse macrophages (FcR3) (19): a corresponding receptor on human
cells has not been demonstrated.
Naturally occurring soluble factors can modulate the activity and the expres-
sion of surface receptors of lymphocytes, monocytes, or granulocytes, Superna-
tant fluids from concanavalin-A treated spleen cells stimulate phagocytosis of
opsonized erythrocytes by mouse macrophages (20), and mixed lymphocyte
culture supernatant fluids induce maturation and FcR appearance in a murine
macrophage line (21). The expression of the murine macrophage FcR for
monomeric IgG2a, but not that of the FcR for aggregated IgG2b, has been
recently shown to be enhanced following infection with BCG in vitro, thus
suggesting that two of the mouse macrophage FcR types can be regulated
independently (22). Medium, conditioned by human mixed leukocyte cultures,
enhances Ab-CMC and formation of rosettes with IgG-sensitized erythrocyte
(EA7S) by the human macrophage cell line U-937 (23, 24). Supernatant fluid of
mixed cultures of human lymphocytes and the Burkitt lymphoma-derived cell
line Daudi induces increased expression of receptors for human IgG1 on the
human promyelocytic cell line HL-60 (25). We have recently shown that medium
conditioned by PHA-stimulated human lymphocytes inducesboth FcRexpression
and ability to mediate Ab-CMC in HL-60 and other promyelocytic cell lines (26).
Crude interferon (IFN) preparations have also been reported to induce a tran-
sient enhancement of FcR expression on human lymphocytes and on lymphoid
B cell lines (27, 28).
In this report, we show that human peripheral blood lymphocytes infected
with different types ofviruses or cultured with certain cell lines produce a factor
that enhances or induces the expression of FcR on human peripheral blood
monocytes, mature PMN, immature myeloid cells and in vitro established mye-
loid and monocytic cell lines. We identify this factor asimmune interferon (IFN-y)
and show that preparations of purified or recombinant IFNy (rIFNT), but not
similar preparations of IFNa or ,d, can induce FcR expression. The FcR induced
by IFNy, like the FcR present on normal mature monocytes but not on freshly
obtained mature PMN, binds monomeric human IgGI with high affinity.
Materials and Methods
Cell Lines.
￿
The human myeloid (HL-60 (29), ML1, ML2, ML3 (30), KG1), monocytic
(U937), erythromyeloid (K562), B-lymphoblastoid (Daudi, Raji, 8866), T-lymphoblastoid
(HSB-2, MOLT/4 and Jurkat), and rhabdomyosarcoma (RDMC) cell lines, the human
fetal skin (HF-28), mouse (LF2) and bovine (CB2) fibroblast strains were grown in our
laboratory in RPMI 1640 medium (Flow Laboratories, Rockville, MD) supplemented with
10% fetal bovine serum (FBS; Gibco Laboratories, Grand Island, NY). B cell linesBC10R
and the human melanoma cell line SK-Mel 23 were kindly provided by Dr. E. De Freitas
and Dr. M. Herlyn (The Wistar Institute).
Viruses. Influenza viruses A/Hong Kong/107/68 (H3N2) (HK), A/PR/8/34
(HON1) (PR8), andA/Japan/305/57 (H2N2) QAP) weregrownin embryonatedchicken
eggs,and had titers of850 hemagglutinating units (HAU)/ml, 1800 HAU/ml, and 2,0001094
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HAU/ml, respectively (allantoic fluid); Herpes simplex virus type 1 (HSV-1) was grown
in Vero cells and had a titer of 108 plaque-forming units (pfu)/ml; the 73-T strain of
Newcastle disease virus (NDV) (allantoic fluid) had a titer of 3.3 X 109 pfu/ml; Sendai
virus had a titer of 512 HAU/ml; vesicular stomatitis virus (VSV) was grown in RDMC
cells and had a titer of 108 pfu/ml.
Peripheral Blood and Bone Marrow Cell Preparations.
￿
Venous peripheral blood samples
were obtained under informed consent from healthy volunteers or from patients with
myeloproliferative diseases or leukemias. Included were samples from seven patients in
the chronic phase of Philadelphia chromosome-positive chronic myelogenous leukemia
(CML), from eight cases of acute myeloid leukemia (AML) at different stages according
to the FAB classification (31) and from four patients with acute lymphatic leukemias
(ALL), two of B- and two of T-cell origin, as diagnosed on the basis of their reaction with
a panel of anti-lymphocyte antibodies. Blood specimens were kindly provided by Dr. P.
Thiagarajan Qefferson Medical College) and Dr. J. Hoxie (University of Pennsylvania).
Hematologically normal bone marrow specimens, obtained for diagnostic purposes at the
Thomas Jefferson University Hospital, were kindly provided by Dr. P. Thiagarajan and
Dr. J. Caro (Jefferson Medical College). The procedures used to prepare peripheral blood
mononuclear cells, lymphocytes (PBL), monocytes (density < 1 .077 g/ml), and PMN
(density > 1 .077 g/ml) have been described in detail (11). Monocyte preparations were
>75% positive for a-naphthyl acetate esterase (a-NAE) and PMN preparations contained
no a-NAE positive cells. Mononuclear nonadherent cells obtained from normal bone
marrow and myeloid leukemia patients were mostly myeloid (from myelocytes to banded
granulocytes) as judged by morphological examination of Giemsa-stained smears and
enzyme cytochemistry.
Nonadherent mononuclear cells from one CML patient were separated into mature
(B13.4 [+]), and immature (B13.4 [-]) cells by an indirect rosetting procedure using
erythrocytes coated by the CrCIB method with goat F(ab')2 anti-mouse Ig, as previously
described (15). Monoclonal antibody B13.4 (IgM) reacts with mature cells of the myeloid
and monocytic lineage, bands and metamyelocytes (32).
&R-Inducing Supernatant Fluids and Interferon (IFN) Preparations.
￿
PBL (107 cells/ml)
were incubated for 18 h at 37°C in RPMI-10% FBS in the presence of the inducer cell
line (106 cells/ml) or with different viruses. Cells were infected with NDV and HSV-1 at
a multiplicity of infection (MOI) of 10; the other virus preparations were used at a 1 :10
final dilution . Cell culture media were harvested, centrifuged, and kept frozen at -80 ° C
until tested . Supernatant fluids (500 ml, concentrated 200 times by vacuum dialysis) were
fractionated by gel filtration on a Sephadex G100 column (bed volume, 480 ml; void
volume, 185 ml) (Pharmacia Fine Chemicals, Uppsala, Sweden). Fractions of 9 ml were
collected, dialyzed against medium, and sterilized by filtration.
Several IFN preparations were used: purified human IFNy (106 U/ml on Hep-2 cells)
was obtained from Interferon Sciences, Inc. (New Brunswick, NJ) . Human rIFN-y, purified
to homogeneity from E. coli, was kindly supplied by Dr. C. G. Sevastopoulos (Genentech
Inc., San Francisco, CA) and it has a titer of ^-107 antiviral U/mg protein on HeLa cells.
Because of the variability of the titer of IFNy on different cell lines and the lack of an
international standard for IFNy, concentrations of rIFNy are expressed in ng/ml rather
than antiviral units (the concentration of 100 ng/ml, most frequently used in these
experiments, corresponds to ^-500 U/ml on HeLa cells). Partially purified IFNa (Leu-
coferon, 106 antiviral units/ml) was obtained from Biotechnologies Inc. (Hartford, CT).
Recombinant types A and D IFNa from E. coli were kindly supplied by Hoffmann-
LaRoche Inc. (Nutley, NJ). Samples of purified IFNO (Prep. 16287) were kindly supplied
by Dr. A. Billiau (Leuven, Belgium). Crude IFNO was obtained from Lee Biomolecular
Research Lab., Inc. (San Diego, CA).
Immunoglobulin Preparations.
￿
Human IgGI was purified from the serum of a patient
affected with multiple myeloma (provided by Dr. P. L. Meroni, Istituto di Clinica Medica
II, University' di Milano, Italy). After labeling with "'I by the chloramine T method (33),
monomeric IgG1 was purified on a Sepharose 6B column (Pharmacia) and used immedi-
ately for binding assays. Supernatants from hybrid cell lines produced in our laboratory,PERUSSIA ET AL.
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containing antibodies specific for cells other than myeloid or monocytic, were used as a
source of monoclonal mouse immunoglobulins. The IgG3 monoclonal antibodies were
kindly provided by Dr. M. Herlyn (The Wistar Institute, Philadelphia, PA). All hybrid
cell cultures were established with a nonsecretor myeloma cell line and contain only one
monoclonal immunoglobulin.
IFN Tests.
￿
Supernatant fluids were tested for antiviral activity by inhibition of the
cytopathic effect of VSV on both bovine (CB2) and human (HF-28) fibroblasts (34).
Human IFNa has antiviral activity on both bovine and human fbroblasts, whereas human
IFNy and ,Q are active only on the human cells (34). Antiviral units are expressed as the
reciprocal of the dilution inhibiting 50% of the cytopathic effect and are equivalent to 1
Reference Unit of the NIH Human reference IFN G-023-901-527.
Induction ofHLA-DR on HumanMelanoma Cell Lines.
￿
Melanoma cellsSK-Mel 23, which
express HLA-DR antigens at low density, were seeded in flat-bottom microtiter plates
(2.0 X 10' cells/well). After an 18-h incubation at 37°C in RPMI 1640-10% FBS, the
medium was replaced with 200 A.l of the appropriate dilution of supernatant fluid or IFN
in triplicate; control wells contained 200,I of medium. After a 48-h incubation at 37°C,
the presence of HLA-DR antigens on the cell membrane was determined in a direct
radioimmunoassay using the IgG2a monoclonal antibody B33.1 directed against a non-
polymorphic determinant of the HLA-DR molecules (14) ('25I-F(ab')2 fragment; 50 ul/
well of a preparation of 10 tag/ml). After a 30-min incubation on ice, cells were washed
four times, removed by trypsinization and the cell-associated radioactivity measured in a
gamma scintillation counter.
Induction ofFcR.
￿
Cells were cultured at 37°C in the presence of different concentra-
tions of FcR-inducing supernatant fluid obtained from HK-infected lymphocytes (HK-
SPN) or of the different IFN types. Cell lines were incubated at a density of 3 X 105/ml;
nonadherent peripheral blood cells, PBL, early myeloid cells and PMN, at 2 X 106/ml;
adherent monocytes were incubated with the different inducers directly in the flasks to
which they adhered. Immediately before testing, the adherent cells were gently scraped
off the flasks in the presence of ethylenediaminetetraacetic acid (EDTA, 0.15 M) using a
rubber policeman. After culture, the cells were washed three times, incubated for 2 h at
37°C in medium without FBS to allow detachment of IgG possibly absorbed from the
serum . When indicated, rabbit anti-human IFNy (final concentration, 250 neutralizing
U/ml, i.e. 1 :40 dilution), sheep anti-human IFNa (10' neutralizing U/ml, i.e. 1 :100
dilution) or normal rabbit serum (NRS) at a 1 :40 final dilution was added during the
incubation with the inducer. The anti-human IFN sera were obtained from Interferon
Sciences, Inc.
Detection ofFcR.
￿
Either 125I-labeled IgGI binding or formation of rosettes with rabbit
IgG (7S) antibody-sensitized ox erythrocytes (EA7S) was used:
(a) BindingAssay with MonomericHumanIgGI .
￿
Cell suspensions (25 ul, usuall~ 20 or 40
X 106 cells/ml) were mixed with 25 ul of serially diluted human monomeric ' 'I-labeled
IgG1 in phosphate-buffered saline (PBS) with 1 % gelatin, 0.1 % NaN3 in a 96-well round-
bottom microtiter plate. All assays were performed in triplicate. After a 2-h incubation at
0°C, the cells were collected, overlayered on FBS in Eppendorf microtest tubes, and
centrifuged for 30 s in an Eppendorf microfuge (Model 5412, Brinkmann Instruments,
Inc. Westbury, NY). The tubes were immediately frozen in dry ice and the pellet-associated
radioactivity, in the resected tips of the tubes, was determined in a gamma scintillation
counter. 'M-labeled IgGI binding in buffer containing the same human myeloma serum
from which the IgGI was purified (5%, vol/vol) was measured in a separate set of tubes
and subtracted from the experimental values, in order to measure only saturable binding.
The data are plotted according to Scatchard (35) as r (number of molecules bound per
cells) vs. rIA-x, where A is the initial molar concentration of IgGI and x, the concentration
of the cell-bound antibody at equilibrium.
(b) EA7S Rosetting. The EA7S indicator system and the rosetting assay have been
described in detail (15). Incubation of the cells with EA7S was carried out for 30 min on
ice to prevent phagocytosis. Cells binding >5EA7S were considered positive. At least 200
viable cells, as judged by erythrosin B dye exclusion, were counted in optical microscopy.1096
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In several experiments, the cell lines were incubated with the inducer in the presence of
cycloheximide (Sigma Chemical Co ., St . Louis, MO) or actinomycin D (Calbiochem-
Behring Corp ., San Diego, CA) in concentrations ranging from 100 to 25 tig/ml and 2
to 0.5 tag/ml, respectively .
Results
Supernatant Fluids from Virus-infected Cells Induce Expression ofFcR on Cells of
Myeloid Origin . Incubation of the HL-60 human promyelocytic cells with me-
dium containing 10% (vol/vol) supernatant fluid from lymphocytes infected with
the HK strain of influenza virus (HK-SPN) induced a significant increase in the
percentage of EA7S rosette-forming cells, from 5-15% in the untreated ones
(Fig. 1, A) up to 100% in the treated ones (Fig . 1,B) . The number of erythrocytes
bound per HK-SPN-treated cell was much higher than that bound per untreated
ones, and the rosettes were more stable . The FcR-inducing factor was present in
FIGURE 1 .
￿
Phase-contrast light microscopy observation of HL-60 cells formingEA7S rosettes
after an 18-h incubation at 37°C in the absence (A) or presence (B) of HK-SPN .
TABLE I
Ability of Viruses and Cell Lines to Induce Peripheral Blood Mononuclear Cells to Produce FcR
Enhancing Activity
*The inducers were incubated for 24 h with each of the three responder populations . Cell-free
supernatant fluid was collected and tested for induction of FcR on HL-60 cells.
$ Peripheral blood mononuclear cells were further separated into plastic adherent and nonadherent
populations . Monocytes (evaluated by a-NAE staining) accounted for 25.4% of the mononuclear
preparation, 0.4% of the nonadherent cells and 75.0% of the adherent cells .
4 Percent EA7S rosette-forming cells (HL-60) after an 18-h treatment with 10% supernatant fluid .
Notdone .
Inducer*
Responder cells$
None HK PR8 JAP HSV-1 NDV Sendai RDMC LF2
Mononuclear cells 7.0 ND" 72.9 ND ND ND ND 7 .4 50.6
Nonadherent cells 6.7 100.0 80.7 85 .1 87.5 100.0 100.0 90 .3 92.6
Adherent cells 6.9 ND 16.7 ND ND ND ND 28.5 48.2the supernatant fluids of lymphocytes infected with a variety of viruses (with a
titer up to 1:500), and in the supernatant fluids from mixed cultures of lympho-
cytes and cell lines (Table I). Control supernatant fluids from lymphocytes or
inducer cells cultured alone, or the direct addition of viruses to the indicator cell
line never induced enhancement of FcR expression (data not shown). Cell
separation experiments indicated that nonadherent peripheral blood mononu-
clear cells were responsible for the production of FcR-inducing factor; neither
separated adherent monocytes (Table 1), nor PMN (not shown) were able to
produce the factor when infected with viruses or cocultured with tumor-derived
cells. All the supernatant fluids, except for those obtained from the coculture
with mouse L cells (not shown), contained high titers of IFNa. The production
of FcR-inducing factor by lymphocytes upon coculture with cell lines was inhib-
ited by the presence of adherent cells. A similar inhibition has been described
for IFN production (36).
Induction of FcR by IFN7.
￿
Different IFN types were tested for their ability to
induce FcR on HL-60 cells. A dose-dependent increase in the percentage of HL-
60 cells able to form EA7S rosettes was observed with recombinant or purified
IFN,y (Fig. 2). The titer of r1FNT was calculated on the basis of a specific activity
of 107 antiviral U/mg protein. As noted in Materials and Methods, the compar-
isonsbetween different typesof IFN basedon antiviral titers should be considered
only approximate. Recombinant IFNa (both A and D) and partially purified
IFNa did not induce expression of FcR even when used at concentrations as
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FIGURE 2.
￿
Enhancement of FcR expression on HL-60 cells treated with different types of
IFN. HL-60 cells (3 X 105/ml) were cultured for 18 h at 37°C in the presence of different
concentrations of IFN preparations. After culture, the cells were washed and EA7S rosette
formation was evaluated as described in Materials and Methods. The broken horizontal line
indicates the percent EA7S rosette-forming cells in the untreated HL-60 cells. Cells were
treated with: ", purified IFN-y; O, rIFN7; A, rIFNA; A, rIFND; 0, purified IFNa; ", purified
IFNO.1098
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high as 10' U/ml. The percentage ofEA7S rosette-formingcellsafter incubation
with partially purified IFNO was slightly increased (up to 38% cellsbound EA7S),
but never reached the values observed after incubation with rIFNy. Kinetic
studies with ML3 and HL-60 as indicator cells, indicated that EA7S rosette
formation was induced as early as 4 and 6 h of incubation with both rIFNy and
HK-SPN, the percentage ofEA-rosette-forming cells reaching a plateau after 12
h of incubation (Fig. 3).
HK-SPN and rIFNy Induce an Increase in the Number of the Binding Sites for
Monomeric Human IgGI on Promyelocytic Cell Lines. Binding studies with
1251
labeled human myeloma IgG1 were performed to measure the variation of the
number ofbinding sites and ofreceptor affinity on HL-60 and ML3 cells treated
with HK-SPN or with rIFNy (Fig. 4). Scatchard plot analysis (Fig. 4, inset)
revealed an increase in the number ofbinding sites for monomeric human IgGI
from 104 on the untreated cells to 4.7 X 104 and 7 X 104 on HL-60 cells treated
with rIFNy or HK-SPN, respectively. The binding affinity, however, was the
same in all the cell preparations tested. (HL-60, K = 1 .5 X 108 M-', HL-60 +
HK-SPN, K = 0.9 X 108 M-'; HL-60 + rIFNy, K = 1.1 X 108 M-'). The 5- to
10-fold increase in the binding sites was reproducibly obtained in several exper-
iments performed on different days with either cell line. >90% of the cells from
the erythromyeloid cell line K562 form stable EA7S rosettes. Scatchard analysis
showed that these cells bind with low affinity (K = 1.8 X 106 M-`) an extremely
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￿
Kinetics of induction of FcR on ML3 (A) and HL-60 (B) cells. ML3 and HL-60
cells were cultured (2.5 X 105 cells/ml) at 37° C in culture medium containing different
inducers. An aliquot of the cells wastaken at the time points indicated, washed, and tested for
FcR expression by EA7S rosette formation. O, control cells incubated in culture medium;*,
cells incubated in the presence of rIFNA (105 U/ml); A, cells incubated in medium containing
10% (vol/vol) HK-SPN; L, cells incubated in medium containing 50 ng/ml of rIFNy.PERUSSIA ET AL.
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FIGURE 4.
￿
Bindingof human monomeric "51-labeled IgGI to HL-60 cells. HL-60cells were
incubated (3 x 105 cells/ml) for 18 h at 37°C with different inducers, washed and tested for
binding of '251-IgGI monomeric human Ig as described in Materials and Methods. ", cells
incubatedin culture medium;A, cells incubated in culture medium containing 10% HK-SPN;
O, cells incubated in the presence of rIFN-y (50 ng/ml). Scatchard plot of results from the
same experiment is shown in the inset. r, number of binding sites;A, molar concentration of
'"I-labeled IgGI added; x, molarconcentration of'25I-labeled IgGI molecules bound; molwt
forhuman IgGI = 150,000.
high number of IgGI molecules (rma, = 1.9 X 106) and that this property is not
modified by treatment with HK-SPN (data not shown).
Characterization of the FcR-Inducing Factor in HK-SPN as IFNy.
￿
To ascertain
whether the increase in the percentage of EA7S rosette-forming cells after
incubation with HK-SPN could be attributed to the presence of IFN, the effect
ofanti-IFNy and anti-IFNa sera on FcR induction was tested. Anti-IFN antibod-
ies (anti-IFNa, 103 neutralizing U/ml; anti-IFNy, 250 neutralizing U/ml) or
NRS were added to cultures of HL-60 cells together with increasing concentra-
tions of rIFNy or HK-SPN. Expression of FcR after culture was measured by
EA7S rosette formation, as described. Ifrabbit anti-IFNy serum was present, no
rosette formation was observed at any of the inducing concentrations of rIFNy
(Fig. 5, left panel) or HK-SPN (Fig. 5, right panel) used. Neither NRS at the
same concentration, nor sheep anti-IFNa serum inhibited the induction of FcR
on HL-60 cells.
The molecular weight ofthe factor present in HK-SPN was determined by gel
filtration. Each fraction eluted was tested for: (a) antiviral activity on C132 and1100
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FIGURE 5.
￿
Effect of anti-IFN sera on FcR induction. HL-60 cells (3 X 105 cells/ml) were
cultured in the presence of increasing concentrations of rIFNy (left panel) or HK-SPN (right
panel) and a constant concentration of anti-IFNy, anti-IFNa antiserum or NRS. Afteran 18-
h incubation, the percentage of EA7S-rosette-forming cells was scored. ", control cells
incubated in culture medium; O, cells cultured in the presence of rabbit anti-IFNy serum
(1 :40 dilution, 250 neutralization units/ml); L, cells cultured in the presence of sheep anti-
IFNa serum (105 neutralization U/ml ; 1:80 dilution); A, cells cultured in thepresence of NRS
(1 :40 dilution).
HF-28 fibroblasts, as measured by the inhibition of cytopathic effect induced on
these cells by VSV (Fig. 6,A); (b) induction of HLA-DR antigens on a human
melanoma line, a specific property of IFNy (37) (Fig. 6,B), and (c) induction of
FcR on HL-60 cells, by 125I-labeled human monomeric IgGI binding assay (Fig.
6, C). The antiviral activity, when tested on CB2 bovine fibroblasts, corresponded
to a single peak with a molecular weight of 20,000. The activity eluted as two
peaks of -40-50,000 and 20,000 molecular weight, respectively, when tested
on HF-28 human fibroblasts. The antiviral activity present in the 20,000-dalton
peak, butnotthat presentin the 40-50,000-dalton peak, was completely inhibited
by sheep anti-IFNa serum. As previously reported (36), the activity of the 40-
50,000 peak, but not that of the 20,000 peak, was destroyed by 56°C or pH 2.0
treatment (not shown). These data indicate that IFNy comprises the high
molecular weight peak, whereas IFNa is present in the low molecular weight
one.
Unseparated HK-SPN enhanced the expression of HLA-DR antigens on the
SK-Mel 23 melanoma cell line. The factor inducing HLA-DR expression was
eluted in the fractions corresponding to an approximate molecular weight of
40-50,000 (Fig. 6,B). Induction of HLA-DR antigens was never observed in the
fractions in which IFNa activity was eluted. Likewise, only the fractions corre-0
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FIGURE 6.
￿
Gel filtration of HK-SPN. 2 ml of 200-fold concentrated HK-SPN was applied to
a Sephadex G100 column. Each 9-ml fraction wasdialyzed against RPMI, filter-sterilized and
tested as described in Materialsand Methods for: (a)antiviral activity on bovine CB2 fibroblasts
(0), human HF-28 fibroblasts (0), and human HF-28 fibroblasts in thepresence ofsheepanti-
IFNa antiserum (A); (b) induction of HLA-DR antigens on SK-Mel 23 human melanoma cell
line (A); (c) induction of bindingof human monomeric 121I-IgGI to HL-60 cells(0). Molecular
weight markers: bovine serum albumin (67K); ovalbumin (43K); chymotrypsin (25K); and
ribonuclease A (13AK).
sponding to a molecular weight of 35-50,000 were able to increase significantly
the '251-labeled IgGI binding on HL-60 cells (Fig. 6,C).
Analysis of the Cell Types on which IFN-y Induces Expression of FcR.
￿
The target
specificity of the FcR enhancing activity of IFNy was tested on cell lines and on
cells freshly obtained from human peripheral blood. Myeloid, B- and T-lymphoid
cell lines were incubated for 18 h at 37 °C in the presence of rIFNy (25 ng/ml)
or rIFNA (103 U/ml). The presence of FcR was tested by the EA7S rosette
assay. Incubation with rIFNy, but not with rIFNA, resulted in a significant
increase in the proportion of EA7S rosette-forming cells with all the myeloid cell
lines tested (Table II). No increase, upon treatment with either of the two IFN
types was observed on erythromyeloid K562 cells, which are spontaneously 98%
positive for EA7S rosetting, nor on any of the B and T lymphoblastoid lines
tested. The same specificity for myelomonocytic cells was also observed when1102
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TABLE II
Effect ofrIFNy and rIFNA on FcR Expression on Human Cell Lines
* Cells (3 X 105/ml) were incubated (18 h at 37°C) in medium with or
without 25 ng/ml rIFNy or 105 U/ml rIFNA.
t Percent EA7S rosette-forming cells.
Not done.
TABLE III
Effect of IFNy andHK-SPN on the Expression ofFcR on Normal and
Leukemic Cells
* Mononuclear cells (2 X 106/ml) were incubated for 18 h at 37 ° C in culture
medium with or without 10% HK-SPN or 50 ng/ml rIFNy.
Number of donors tested.
§ Percent EA7S rosette formingcells. Individual values are givenwhen less than
three donors were tested, and mean ± SD when three or more donors were
tested.
Treatment*
Cell lines
None rIFNy rIFNA
Myeloid
HL-60 15.1$ 84.4 16.3
ML1 78.8 87 .9 NDQ
ML2 71 .2 88 .3 ND
ML3 15.5 76.3 14.8
KG1 3.7 44 .6 11 .0
U937 42.5 83 .3 50.9
K562 98.0 99 .0 ND
Lymphoid
Borigin
Raji 0.0 0.0 0.0
Daudi 6.6 11 .2 6.1
8866 0.9 0.9 0.0
BC10R 12.0 12 .0 14.6
T origin
HSB-2 0.0 0.0 0.0
Molt 4 0.0 0.0 0.0
jurkat 3.6 0.9 0.8
Responder cells
None
Treatment*
HK-SPN rIFNy
Normal bone marrow (2)* 14.6, 50 56.5, 31 .2 56.1, 45.6
Chronic myelogenous leukemia (7) 22.9 ± 18.3 68 .9 ± 12.8 58.2 ± 16.1
Myelofibromatosis 6.5 37 .2 45.6
AML (M1)(3) 1.8±3.2 3.8±6 .5 6.7±7.2
AML (M2)(4) 6.4±5.5 3.0±7 .3 15.0±9.1
AML (M3) 1.9 6.7 20.0
AML (M4) (2) 16.8, 39 .2 20 .8, 56.7 52.6, 81 .2
ALL (pre-B) (2) 2.0, 0.0 0.0, 3.4 0.0, 0.0
ALL (T) (2) 0.0, 0.0 0.0, 0.0 0.0, 3.4PERUSSIA ET AL.
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normal bone marrow or leukemic peripheral blood cells were tested (Table III).
Both HK-SPN and rIFNy were able to induce FcR expression on nonadherent
mononuclear cells obtained from two normal marrow specimens at levels signif-
icantly higher than on untreated cells. A variable proportion of cells (22.9 ±
18.3) in nonadherent mononuclear cells from the peripheral blood of seven
CML patients formed EA7S rosettes. In all cases, theproportion ofEA7S-rosette-
forming cells increased after incubation with either inducer. The same results
were obtained with nonadherent mononuclear cells from a patient affected with
myelofibromatosis. Cells from 10 AML patients were tested: upon treatment
with rIFNy, FcR was induced in a small proportion of cells obtained from the
patients with M1, M2, and M3 leukemias; significant FcR increase was observed
with the cells of the two patients with myelomonocytic leukemia (M4). rIFNy
was always more efficient than HK-SPN in inducing FcR on AML cells, as well
as on myelofibromatosis and bone marrow cells. In none of the four ALL tested
(two ofB- and two ofT-cell origin) was FcR expression increased upon treatment
with either HK-SPN or rIFNy.
Increased Numbers of FcR for Human Monomeric IgGI are Induced by rIFNy on
Peripheral Blood Monocytes and PMN. Normal peripheral blood monocytes and
PMN were incubated (18 h at 37°C) in RPMI-10% FBS containing 50 ng/ml of
rIFNy. After washing, the binding assay of '2'I-labeled human IgGI was per-
formed as described. Scatchard plot of the results obtained with monocytes in
one typical experiment out ofsix performed with similar results is shown in Fig.
7. The number of FcR binding sites on monocytes after incubation with rIFNy
was increased 2.1- to 5.2-fold (from 10,461 ± 3,585 to 32,059 ± 13,662 per
cell). HK-SPN was unable to induce an increase ofFcR expression on monocytes.
rIFNA did not increase FcR by itself and it partially prevented the induction by
IFNy (not shown). This inhibitory effect of rIFNA was not observed on the
myeloid cell lines, on which the HK-SPN is effective. The Scatchard plot ofthe
binding of IgGI to uninduced monocytes was not perfectly linear and did not
provide an accurate determination of the affinity of the receptor (Fig. 7). The
FcR on rIFNy-induced monocytes has an affinity (K = 1.58 ± 0.81 x 108 M-'),
comparable to that observed on both induced and uninduced HL-60 cells. On
PMN from three different donors tested in the same experiment (Fig. 8), rIFNy
induced the appearance of 13,641 ± 2,374 specific binding sites per cell with an
averageaffinity of 1.32 ± 0.28 x 108 M-'. Untreated PMN did not show specific
high affinity binding for monomeric IgGI . The reactivity ofantibody B73.1 on
the PMN preparations, as analyzed by indirect immunofluorescence (flow cyto-
fluorometry), was not affected by treatment with rIFNy (data not shown). Table
IV shows the results obtained in one experiment ofbindingofhuman monomeric
IgGI to myeloid cells at different stages of maturation obtained from the
peripheral blood ofa CML patient. The myeloid cells have been separated into
cells with d > 1 .077 g/ml (mostly mature PMN); nonadherent cells with d <
1.077 g/ml, reacting with antibody B13.4 (32) (metamyelocytes and bands) ;
nonadherent cells, not reacting with B13.4 (mostly myelocytes); and adherent
cells with d < 1 .077 g/ml (mostly monocytes). Only monocytes and, among the
myeloid cell preparations, the B13.4(+) cells showed significant binding on day
0. A marked increase in the number of IgGI molecules bound per cell was1104
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FIGURE 7. Enhancement of expression of FcR for human monomeric IgGI on normal
peripheral blood monocytes. Binding assay of human monomeric "'I-labeled IgGI was
performed as described in Materials and Methods, on adherent peripheral blood monocytes
from one donor. Data were plotted accordingto Scatchard. Monocytes were incubated with:
A, culture medium; A, HK-SPN (10%, vol/vol); ", rIFNA (10' U/ml); O, rIFN7 (50 ng/ml).
observed in all cell preparations after an 18-h incubation in the presence of
rIFNy; this increase was particularly evident in the B13.4 (+) cells. In this
experiment, incubation of monocytes at 37°C for 18 h determined a decrease in
binding: the presence of rIFNy during the incubation simply maintained the
original binding ability. A similar but more modest decrease of binding ability,
upon an 18-h incubation, was sometimes observed with cultures of normal
monocytes, in agreement with previous reports (26). However, monocytes from
normal donors, cultured in the presence of rIFNy, always showed a several-fold
increase in binding ability over that observed at the beginning of the culture
(not shown).
hnmunoglobulin Subclass Specificity of the FcR Induced by rIFNy on Myeloid
Cells. The specificity of the FcR induced, on cells of myeloid origin, by rIFNy
was tested in competition experiments in which monoclonal mouse immunoglob-
ulins were used as cold competitors for . ..I-labeled monomeric human IgGI .
Cold human IgGI completely blocks the binding of the I21I-labeled IgGI . Only
IgG2a and IgG3 mouse immunoglobulins were able to inhibit human IgGI
binding on monocytes, both untreated (Fig. 9,a) and treated with rIFNy (Fig.
9,b). The same results were obtained when untreated (Fig. 9,c) and rIFNy-
treated HL-60 cells (Fig. 9,d), or rIFNy-induced peripheral blood PMN (not
shown) were tested.
rIFNy-Dependent FcR Induction on Myeloid Cell Lines: Sensitivity to RNA andN
O
%X
Q
Cell preparation*
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FIGURE 8. Induction of FcR for human monomeric IgGI on normal peripheral mature
PMN. Bindingof human monomeric '251-labeled IgGI was performed, as described, on PMN
preparations (20 x 106 cells/ml) from three different normal donors incubated for 18 h at
37°C in culture medium (0,O, A) or in medium containing 50 ng/ml rIFNy (0, 0, A). Data
were plotted according to Scatchard.
TABLE IV
Binding ofiWonwneric Human IgGl to Peripheral Blood Cellsfrom a
CML Patient
d < 1 .077, nonadherent, B13.4 (-)
d< 1.077, nonadherent, B13.4 (+)
d7 1.077, PMN
d< 1 .077, adherent
* Cells at different stages of maturation were obtained as described in
Material and Methods.
Cellswere tested immediately afterseparation or afteran 18-h incubation
in culture medium or in the presence of 50 nglml of rIFNy.
$ Number of '251-labeled IgGI molecules bound per 106 cells after a 2-h
incubation at 4°C with 15 nM'25I-labeled IgGI .
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Protein Syrathesis Inhibitors. To ascertain whether de novo RNA and protein
synthesis are necessary in the myeloid cells in order to express FcR upon
induction with rIFNy, cycloheximide (in concentrations ranging from 50-200
,ug/ml) and actinomycin D (0.5-2 Ng/ml) were added to the cells (HL-60 and
ML3) during an 8-h incubation in the presence of 50 ng/ml of rIFNy. The
background percentage of EA7S rosette-forming cells in the HL-60 and ML3
1,740 2,564 9,394
4,067 6,559 23,403
2,544 2,813 5,654
12,222 4,162 9,6521106
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FIGURE 9.
￿
Mouse IgG isotype specificity of theFcR for human monomeric IgGI inducedby
rIFNyon myeloid cells. Target cells were: a, normal peripheral blood monocytes; b, peripheral
blood monocytes induced by rIFNy (50 ng/ml); c, HL-60 cells; d, rIFNy treated HL-60 cells
(50 ng/ml). Induction andinhibition experiments were as describedin Materialsand Methods.
Points represent individual monoclonal antibodies tested of the indicated Ig subclass. Broken
lines indicate the number of "5I-labeled human monomeric IgGI moleculesbound/ 10' cells
in the absence of cold competitor Ig.
cell lines was 16.7% and 10%, increasing upon 8-h incubation with rIFNy to
65.7% and 71.2%, respectively. Both cycloheximide and actinomycin D, at the
concentrations used, reduced the number ofrosette-forming cells to values close
to background values.
Discussion
A lymphokine able to rapidly enhance the expression of the FcR for IgGI
present on human cell lines is contained in medium conditioned by mixed
leukocyte cultures (23, 25). In this report, we identify the lymphokine able to
induce FcR as immune IFN. We demonstrate that IFN-y selectively induces the
expression of the high-affinity FcR for monomeric human IgGI on both human
monocytic and myeloid cells, including mature peripheral blood PMN, which do
not spontaneously express this type of FcR.
a
----------- ---------
b _
__________S.________
"
"
C
S
"
"
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As a source of the FcR-enhancing lymphokine, we used supernatant fluids
from human leukocytes infected with a variety of viruses or cultured with cell
lines . Infection of fibroblasts with HSV has been reported to induce FcR
expression (39) ; infection ofmyelomonocytic cells with the other virus types that
we used for supernatant fluid production did not directly induce FcR, showing
that a lymphokine and not the virus itself was responsible for the FcR induction .
Treatment of the supernatants at pH 2 .0, a procedure performed to inactivate
the infectious viruses, also inactivated the lymphokine . The identification of the
factor present in the leukocyte supernatant fluids, specifically in HK-SPN, as
immune interferon is supported by both indirect and direct evidence .
The production of IFNy in lymphocyte cultures incubated with influenza
viruses for 24 h has been considered dependent on the sensitization of the
lymphocyte donors to the virus (40, 41) . However, we have shown previously
that lymphocytes cultured with cell lines or with viruses, such as NDV, against
which donors are rarely sensitized, consistently produce IFNy together with
IFNa in less than 24 h (36) . Induction of IFNy does not seem to depend on
alloantigenic stimulation under these experimental conditions, because a rapid
production of IFNy in response to alloantigens is observed only when primed
lymphocytes are used (34), and autologous derived cell lines are able to induce
IFNy production (36) . The addition of an anti-IFNy antiserum to the cultures
of HL-60 cells containing HK-SPN completely abrogated FcR induction, as
tested by EA7S rosette formation . In those experiments, the induced cells were
washed free of serum and preincubated for 2 h at 37°C in serum-free medium
to avoid competition of the IgG contained in the serum for the binding to the
FcR . Under those conditions, normal rabbit IgG or IgG aggregates present in
the serum do not prevent detection of the FcR . The FcR of monocytes is
modulated after interaction with immune complexes (42, 43). However, the
inability of an anti-IFNa antiserum, reacting with and inactivating the IFNa
present at high titer in the HK-SPN, to prevent FcR enhancement excludes the
possibility that modulation of the FcR is induced by IFN-anti IFN immune
complexes .
The FcR enhancingactivity contained in HK-SPN waseluted from a Sephadex
G100 column in the fractions corresponding to a molecular weight of 40-
50,000 . These fractions contained antiviral activity not inhibitable by the anti-
IFNa antiserum and detectable onlyon homologous human fibroblasts .A second
peak, corresponding to a molecular weight of 20,000, containedantiviral activity
that was identifiable as IFNa by its activity on both human and bovine cells (34)
andby its complete inhibition with anti-IFNa antiserum . The fractionscontaining
this second peak of antiviral activity had no effect on FcR expression . The same
fractions from the G100 column that induced FcR expression were also able to
induce expression of HLA-DR antigens (as detected by antibody B33.1) on
human melanoma cells. The presence of anti-IFNy serum during the induction
completely abolished the ability of these fractions, of HK-SPN and of other
leukocyte-conditioned media, to induce expression of HLA-DR on both mela-
noma and on the ML3 promyelocytic cell line .
Crude or partially purified preparations of human IFNa have been reported
to induce a modestand transient enhancementofFcRexpression on lymphocytes1108
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and lymphoid and nonlymphoid cell lines (27, 28, 45). However, the results of
our tests of several IFN preparations for their ability to induce FcR expression
provide a direct demonstration that IFNy is responsible for the induced expres-
sion of FcR for monomeric IgG1 on human cells ofmyeloid origin . Only purified
IFNy and rIFNy produced in E. colt were able to enhance or induce FcR
expression ; using different preparations of IFNa or IFNO, we observed no effect
on FcR expression in either myelomonocytic or lymphoid human cells. Similar
to our findings with human cells, IFNy has been shown to enhance FcR expres-
sion on mouse macrophages (46).
The effect of IFN on FcR expression is prevented in the presence of cyclohex-
imide or actinomycin D, as are most of the antiviral and anticellular effects of
IFN, which require active RNA and protein synthesis: this fact is generally
interpreted as a requirement for the synthesis of a second intracellular mediator
of proteinaceous nature (47). The molecular mechanism by which IFN induces
or increases the expression of FcR or other surface proteins, such as HLA-A,B,C
and HLA-DR antigens (48) is not known. The rapid induction of FcR on the
IFN-treated cells might be due to changes in cellular membrane properties (49,
50) that allow the expression of previously undetectable preformed receptors,
and not to de novo synthesis.
The expression of FcR during myeloid differentiation induced by chemical
inducers (32) or by leukocyte-conditioned medium (26), represents only one of
many different morphological, enzymatic, andphenotypic parameters of induced
maturation (26, 51). In the presence of IFNy, FcR expression in myelomonocytic
cells is at a maximum by 8 h after the beginning of the culture and is maintained
forat least 72 h; at least during the initial 24 h, FcR expression is notaccompanied
by other morphological or cytochemical changes or functional activities (e .g. Ab-
CMC) characteristic of differentiated myeloid cells. Although these data might
suggest a separate regulation of differentiation and induction of FcR on myeloid
cells, recent evidence indicates that immune IFN is the major factor in condi-
tioned medium from lectin-stimulated leukocytes responsible for the induction
of differentiation of myeloid cellsalongthe monocyticpathway(Dayton, Perussia,
and Trinchieri, manuscript in preparation).
Our analysis of the effect of IFNy on cell lines and on fresh cells from patients
or healthy donors shows that FcR expression is enhanced or induced only on
cells of myelomonocytic origin. K562 cells, which have a dual differentiation
potential toward erythroid or myeloid cells (52), never showed an increase in the
number of FcR receptor binding sites for human IgGI . These cells bind with
very low affinity monomeric human IgGI, and the 72,000-dalton IgG binding
protein, characteristic of human monocytes, has not been precipitated from these
cells (12). Instead, IgG binding ability of K562 cells has been associated with a
43,000-dalton protein, possibly identified as actin (12). Though HK-SPN and
IFNy had a similar FcR enhancing ability on cell lines, only IFNy was effective
on fresh monocytes. It is possible that the inability of HK-SPN to induce FcR on
fresh monocytes is due to the inhibitory effect of the IFNa contained in the
preparation, as preliminary experiments have shown that IFNa is able to block
the IFNy-mediated enhancement of FcR and the HK-SPN contains predomi-
nantly IFNa. The ability of different cell types to respond to HK-SPN would bePERUSSIA ET AL.
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inversely correlated with their susceptibility to the effect of IFNa: this might
explain the observation that IFNy was more effective than HK-SPN in inducing
FcR on AML cells. A several-fold increase in the number of IgGI molecules
bound per cell, similar to observations on monocytes and on HL-60 and ML3
promyelocytic cell lines, was also observed after IFNy treatment on both mature
(813.4[+]), and immature (B13 .4[-]) myeloid cells obtained from the peripheral
blood of CML patients. IFNa and 0 preparations did not significantly increase
the number of binding sites even when used at concentrations of 108 U/ml.
These data show that myeloid cells at any stage ofmaturation, from myelocytes
or more immature cells, to metamyelocytes and mature neutrophils, can be
induced by IFNy to express FcR. The significant enhancement of FcR on the
more differentiated M3 and M4AML, compared with themodest effect observed
in most cases of MI and M2, suggests that the ability to respond to IFNy with
FcR induction might be acquired at the promyelocytic stage. Data showing that
the promyelocytic cell lines HL-60 or ML3 are more sensitive responders to
IFNy than the myeloblastic line KG1 support this hypothesis.
The binding equilibrium constant of the FcR induced on promyelocytic cell
lines and on peripheral blood monocytes (1.44 ± 0.51 X 108 M-' and 3.01 ±
0.81 X 108 M-', respectively) was not appreciably affected by IFNy treatment.
The equilibrium constant could not be accurately determined on fresh mono-
cytes, because the Scatchard plot was not perfectly linear, as reported by other
authors (13, 38).
The ability of IFNy to induce on mature PMN a number of binding sites
(13,641 ± 2,374) similar to that of resting monocytes, with an affinity (1.32 ±
0.30 X 108 M-') of the same order ofmagnitude as that of monocytes or of HL-
60 cells was an unexpected finding. The FcR induced on PMN is inhibited by
the same mouse IgG isotypes as the FcR of monocytes and HL-60 cells. Mature
PMN, in agreement with previous reports (9), do not express high affinity
receptors for monomeric IgG. Morphological observation of EA7S rosette-
forming PMN preparations shows both increased numbers of rosettes and of E
bound per cell, confirming that IFNy affects PMN and not contaminant mono-
cytes. However, IFNy does not induce any increase in the expression of the
873.1 antigen, present at variable density on the PMN ofdifferent donors, and
representing the receptor for aggregated immunoglobulins or a molecule func-
tionally associated with it (14). This is in agreement with our previous report
that IFN does not affect the expression ofthe B73.1 antigen on human NK cells
(15). Our results recall the recent findings that activation ofmurine macrophages
selectively enhances expression ofthe FcRI for monomeric IgG2a, whereas the
expression of the FcR2 for aggregated IgG2b is decreased (22). Unlike mature
PMN, immature myeloid cells from CML patients show a low but significant
binding of monomeric IgGI even in the absence of IFNy stimulation. The
presence of the receptor for monomeric IgG on immature myeloid cells might
be transient and restricted to specific stages of normal neutrophil maturation.
Alternatively, a population ofcells with intermediate myelomonocytic character-
istics might exist in the peripheral blood of CML patients.
To define the specificity of the induced human FcR and to compare it with
the specificity of the better characterized murine FcR, we also tested the ability1110
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of mouse monoclonal IgG of'different isotypes to inhibit human IgGI binding.
This approach seemed validbased on the biochemical similaritiesbetween human
monocyte FcR and murine FcRI and between the human PMN FcR and murine
FcR2. Mouse IgG isotypes are easily obtained from supernatant fluids ofmurine
somatic B-cell hybrid cultures, enabling a better comparison of the human and
the mouse FcR. Moreover, in the light ofcurrent therapeutic attempts in humans
using murine monoclonal antibodies, information on the ability of the various
isotypes to bind to different human FcR, characteristics of cells with different
effector functions, might help in interpreting the possible in vivo effects of these
murine Ig isotypes. Our results show that culture supernatants containing IgG2a
and IgG3, but not those containing IgGI or IgG2b, efficiently compete with
human IgGI for binding to monocytes, IFNy-treated PMN and promyelocytic
cell lines. These results confirm the similarities of the human FcR induced by
IFNy with the mouse FcR1. However, in the mouse, binding of IgG3 to the
FcR1 has not been observed and the receptor for IgG3 has been described as a
separate, low affinity receptor. This finding might suggest a minor divergence
of the human FcR during evolution. Our observation that IFNy enhances FcR
expression on human myelomonocytic cells with specificity for some isotypes of
mouse monoclonal antibodies, together with the ability of IFNy to induce
immature myeloid cells and monocytes to exert antibody-dependent cytotoxicity,
mediated through the FcR (unpublished results), suggest the possibility that
IFNy and mouse monoclonal antibodies might have a synergistic therapeutic
effect, e.g. in tumor cell destruction.
Summary
We report here that FcR for human monomeric IgGI can be induced on cells
of myeloid origin cultured in the presence of IFNy for 8 h. Supernatant fluids
from cultures of lymphocytes infected with a variety of viruses or cocultured
with cell lines have the same FcR enhancing effect as IFNy. We identify the
factor in the supernatant fluid responsible for the induction as immune inter-
feron. Among the different types of IFN, only the y type (both purified and
recombinant) specifically induces the appearance of FcR for monomeric IgGI
on normal and leukemic myeloid cells but not on cells of lymphoid origin. This
effect is also evident on mature PMN. We show that the specificity and the
affinity of the receptor induced on HL-60 promyelocytic cells, peripheral blood
monocytes, and PMN are identical to those ofthe receptor spontaneously present
on the same cells, except for PMN, which do not spontaneously express this type
of receptor. The results ofinhibition experiments performed with mouse IgG of
different isotypes indicate that the receptor can be inhibited by murine IgG2a
and IgG3. These results suggest that the receptor present on human monocytes
or immature myeloid cells, selectively inducible by IFNy, has a specificity similar
to the FcRI described on mouse macrophages.
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